Agenda Details

Learn more about sessions and presentations at the 26th Annual Meeting

Detailed Program

Market Approved Therapies- Focus on ex vivo Lenti Gene Therapy to Cover Other Technologies

Jasmine Greenamyer. Bristol Myers Squibb, DC

Disclosures: J. Greenamyer: None.

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.